Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ASRT

ASRT - Assertio Therapeutics Inc Stock Price, Fair Value and News

1.16USD0.00 (0.00%)Market Closed

Market Summary

ASRT
USD1.160.00
Market Closed
0.00%

ASRT Alerts

  • 2 major insider buys recently.

ASRT Stock Price

View Fullscreen

ASRT RSI Chart

ASRT Valuation

Market Cap

110.3M

Price/Earnings (Trailing)

-0.33

Price/Sales (Trailing)

0.78

EV/EBITDA

-0.3

Price/Free Cashflow

3.27

ASRT Price/Sales (Trailing)

ASRT Profitability

EBT Margin

-177.99%

Return on Equity

-247.57%

Return on Assets

-118.09%

Free Cashflow Yield

30.6%

ASRT Fundamentals

ASRT Revenue

Revenue (TTM)

142.1M

Rev. Growth (Yr)

-23.59%

Rev. Growth (Qtr)

-1.63%

ASRT Earnings

Earnings (TTM)

-333.0M

Earnings Growth (Yr)

-29.45%

Earnings Growth (Qtr)

92.14%

Breaking Down ASRT Revenue

Last 7 days

10.5%

Last 30 days

11.5%

Last 90 days

11.5%

Trailing 12 Months

-81.1%

How does ASRT drawdown profile look like?

ASRT Financial Health

Current Ratio

1.87

Debt/Equity

0.29

Debt/Cashflow

0.89

ASRT Investor Care

Shares Dilution (1Y)

70.89%

Diluted EPS (TTM)

-4.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024142.1M000
2023162.2M168.0M169.4M152.1M
2022120.7M130.5M139.2M156.2M
2021112.2M117.0M107.9M111.0M
2020198.7M167.9M137.1M106.3M
2019000229.5M

Tracking the Latest Insider Buys and Sells of Assertio Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 11, 2024
vacirca jeff l
bought
11,100
1.11
10,000
-
Jun 05, 2024
mason heather l
bought
24,250
0.97
25,000
interim executive officer
May 23, 2024
emany sravan kumar
acquired
-
-
53,750
-
May 23, 2024
kirk sigurd
acquired
-
-
53,750
-
May 23, 2024
staple peter d
acquired
-
-
53,750
-
May 23, 2024
vacirca jeff l
acquired
-
-
53,750
-
May 23, 2024
mckee william
acquired
-
-
53,750
-
May 12, 2024
patel ajay
sold (taxes)
-32,332
0.96
-33,680
svp and cfo
May 12, 2024
patel ajay
acquired
-
-
76,034
svp and cfo
May 12, 2024
schlessinger sam
acquired
-
-
76,034
svp, general counsel

1–10 of 50

Which funds bought or sold ASRT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
added
24.96
3,000
28,000
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-37.34
-6,849
8,780
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-54.3
-38,471
26,705
-%
May 16, 2024
ALETHEA CAPITAL MANAGEMENT, LLC
reduced
-3.99
-19,939
123,220
0.10%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
reduced
-73.25
-37,217
11,743
-%
May 15, 2024
Squarepoint Ops LLC
reduced
-24.04
-27,219
58,119
-%
May 15, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
reduced
-41.49
-330,789
364,934
0.01%
May 15, 2024
BARCLAYS PLC
reduced
-46.13
-72,000
67,000
-%
May 15, 2024
Gotham Asset Management, LLC
reduced
-41.55
-13,382
14,733
-%
May 15, 2024
Federation des caisses Desjardins du Quebec
new
-
376
376
-%

1–10 of 43

Are Funds Buying or Selling ASRT?

Are funds buying ASRT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ASRT
No. of Funds

Unveiling Assertio Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
continental general insurance co
-
0
SC 13G/A
Feb 14, 2024
armistice capital, llc
6.13%
5,800,000
SC 13G/A
Feb 14, 2024
nantahala capital management, llc
8.0%
7,619,440
SC 13G
Feb 13, 2024
vanguard group inc
5.15%
4,878,543
SC 13G
Jan 26, 2024
blackrock inc.
6.9%
6,574,483
SC 13G
May 05, 2023
continental general insurance co
6.7%
96,426
SC 13G
Jan 27, 2022
highbridge capital management llc
0%
0
SC 13G/A
Feb 16, 2021
d. e. shaw & co, l.p.
2.2%
2,321,422
SC 13G/A
Feb 11, 2021
renaissance technologies llc
6.08%
6,522,314
SC 13G/A
Feb 04, 2021
ci investments inc.
5.63%
6,258,862
SC 13G/A

Recent SEC filings of Assertio Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 12, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 04, 2024
3
Insider Trading
Jun 04, 2024
4
Insider Trading
May 30, 2024
8-K
Current Report
May 29, 2024
8-K
Current Report
May 29, 2024
S-8
Employee Benefits Plan
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading

Peers (Alternatives to Assertio Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
357.9B
85.6B
-3.11% -10.20%
9.3
4.18
5.68% 202.39%
330.7B
61.4B
-0.40% 14.82%
143.41
5.39
6.11% -82.30%
165.3B
29.5B
-0.40% 34.19%
43.93
5.6
12.76% -52.47%
157.2B
35.0B
-6.28% -28.38%
135.28
4.49
-26.40% -92.03%
88.0B
27.4B
4.20% -9.55%
181.67
3.21
1.51% -91.32%
19.1B
16.0B
0.53% 124.77%
-38.54
1.19
7.23% 71.10%
MID-CAP
4.2B
1.7B
3.02% -25.84%
9.71
2.44
54.01% 364.56%
3.5B
4.6B
-12.14% -24.54%
-456.23
0.77
-0.06% 94.55%
2.5B
9.0B
7.06% -6.96%
-5.5
0.28
10.01% -27.45%
2.0B
676.2M
-6.90% -30.70%
12.79
2.93
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-10.75% 3.11%
-3.65
1.73
24.65% 80.36%
21.9M
1.3M
-11.21% -52.08%
-2.96
16.83
-98.14% -104.71%
15.8M
89.6M
-10.58% -19.13%
-1.11
0.19
287.27% -129.41%
2.2M
21.5M
-15.79% -88.85%
-0.28
0.1
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Assertio Therapeutics Inc News

Latest updates
Simply Wall St07 May 202407:00 am
InvestorPlace10 months ago

Assertio Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Revenue-1.6%32,44832,98535,62740,99142,46650,35234,21235,13136,53833,32925,47225,37326,83930,17634,56520,61720,91738,03255,14757,203
Costs and Expenses-43.7%36,78565,314263,89828,57137,82239,73027,77824,34024,97925,34719,53837,37419,33263,27241,24046,36937,549-65,28053,585
  S&GA Expenses-22.7%18,52423,95821,00516,77116,90413,70411,90010,54310,63811,2649,01324,0408,32421,27227,60728,13127,314-36,11724,755
  R&D Expenses-28.4%7331,0241,316503----------------
EBITDA Margin-11.8%-1.59*-1.42*-1.07*0.30*0.30*0.42*0.47*0.51*0.37*0.35*-0.02*-0.14*--------
Interest Expenses-----9,918-1,163--2,3272,4372,4952,6052,6842,5983,0501,6048,674-13,87214,842
Income Taxes-99.6%10025,45950,7003,860-2,110-79,97521059371343446.00-300548-10,9951,050-9,4722,048--1,7151,141
Earnings Before Taxes86.3%-4,378-31,905-228,88512,330-5,5948,5784,3848,4279,7775,0413,783-14,4695,092-35,348-9,472-43,97143,278-1,616-12,464
EBT Margin-6.5%-1.78*-1.67*-1.26*0.12*0.10*0.20*0.20*0.21*0.03*0.00*-0.38*-0.46*--------
Net Income92.1%-4,510-57,384-279,5448,470-3,48488,5534,1747,8349,0644,6073,737-14,1694,544-24,353-10,522-34,49941,230-192,6263,331-13,605
Net Income Margin-7.4%-2.34*-2.18*-1.10*0.58*0.60*0.70*0.18*0.19*0.03*-0.01*-0.28*-0.38*--------
Free Cashflow32.1%7,4085,6072,57918,32722,44326,42310,04514,37727,3734,0784,654964--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Assets-1.6%282286380405414414323322339327299312325303333346527
  Current Assets0.8%17217118513413813212611712510311311912494.00104135104
    Cash Equivalents9.9%81.0073.0077.0070.0069.0065.0065.0052.0061.0037.0059.0054.0061.0021.0035.0059.0042.00
  Inventory2.4%39.0038.0043.0019.0016.0014.0014.0012.009.007.005.007.009.0012.0013.0025.003.00
  Net PPE-8.6%1.001.001.001.001.001.001.001.001.002.002.002.002.002.004.007.003.00
  Goodwill---20.00-----------9.009.00-
Liabilities-0.6%147148187151164188188194227224202220220248257261469
  Current Liabilities-1.1%92.0093.0011479.0095.0095.0092.00116139135100117109133131134185
  Long Term Debt0.3%39.0039.0039.0038.0038.0066.0066.0050.0061.0061.0066.0067.0072.0072.0077.0092.00271
    LT Debt, Current-----0.000.00---12.00---12.00--80.00
    LT Debt, Non Current0.3%39.0039.0039.0038.0038.0066.0066.0050.0061.0061.0066.0067.0072.0072.0077.0092.00271
Shareholder's Equity-2.5%13413819325425122613512811210297.0092.0010556.0076.0085.0058.00
  Retained Earnings-0.7%-656-651-594-314-323-319-408-412-420-429-433-437-423-427-403-393-399
  Additional Paid-In Capital0.1%791790787569574545543541532532531530529483480478458
Shares Outstanding0.5%95.0095.0095.0057.0051.0048.0048.0046.0045.0045.0043.0041.00-----
Float----296---140---68.00---90.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Cashflow From Operations31.6%7,5085,7072,57918,60122,71726,69710,04514,43027,4264,1314,654964-4,226-5,982-14,431-20,096-25,063---
  Share Based Compensation-54.3%1,2072,6421,8652,2052,4462,3882,4001,7349829498679577723,8861,5113,5931,934---
Cashflow From Investing100.0%--2394,144-703-105-25,784-371-16,114-404-18,525-----1.0063,766449,036---
Cashflow From Financing97.7%-206-8,915-10.00-16,326-18,950-7982,888-7,441-2,443-7,522-356-7,56944,473-7,969-10,234-90,240-360,107---
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ASRT Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 32,448$ 42,466
Costs and expenses:  
Cost of sales11,1775,467
Research and development expenses7330
Selling, general and administrative expenses18,52416,904
Change in fair value of contingent consideration09,167
Amortization of intangible assets5,6316,284
Restructuring charges7200
Total costs and expenses36,78537,822
(Loss) income from operations(4,337)4,644
Other (expense) income:  
Debt-related expenses0(9,918)
Interest expense(757)(1,122)
Other gain716802
Total other expense(41)(10,238)
Net loss before income taxes(4,378)(5,594)
Income tax (expense) benefit(132)2,110
Net loss and comprehensive loss$ (4,510)$ (3,484)
Basic net loss per share (in dollars per share)$ (0.05)$ (0.07)
Diluted net loss per share (in dollars per share)$ (0.05)$ (0.07)
Shares used in computing basic net loss per share (in shares)94,98051,005
Shares used in computing diluted net loss per share (in shares)94,98051,005
Product sales, net  
Revenues:  
Total revenues$ 31,862$ 41,769
Royalties and milestones  
Revenues:  
Total revenues$ 586$ 697

ASRT Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 80,743$ 73,441
Accounts receivable, net42,61047,663
Inventories, net38,60237,686
Prepaid and other current assets10,51912,272
Total current assets172,474171,062
Property and equipment, net704770
Intangible assets, net105,701111,332
Other long-term assets3,0863,255
Total assets281,965286,419
Current liabilities:  
Accounts payable15,65013,439
Accrued rebates, returns and discounts57,87058,137
Accrued liabilities15,40118,213
Contingent consideration, current portion2,7002,700
Other current liabilities823954
Total current liabilities92,44493,443
Long-term debt38,62138,514
Other long-term liabilities16,40616,459
Total liabilities147,471148,416
Commitments and contingencies (Note 15)
Shareholders’ equity:  
Common stock, $0.0001 par value, 200,000,000 shares authorized; 95,115,452 and 94,668,523 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.99
Additional paid-in capital790,538789,537
Accumulated deficit(656,053)(651,543)
Total shareholders’ equity134,494138,003
Total liabilities and shareholders' equity$ 281,965$ 286,419
ASRT
Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
 CEO
 WEBSITEassertiotx.com
 INDUSTRYPharmaceuticals
 EMPLOYEES30

Assertio Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Assertio Therapeutics Inc? What does ASRT stand for in stocks?

ASRT is the stock ticker symbol of Assertio Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Assertio Therapeutics Inc (ASRT)?

As of Fri Jun 21 2024, market cap of Assertio Therapeutics Inc is 110.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ASRT stock?

You can check ASRT's fair value in chart for subscribers.

What is the fair value of ASRT stock?

You can check ASRT's fair value in chart for subscribers. The fair value of Assertio Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Assertio Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ASRT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Assertio Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ASRT is over valued or under valued. Whether Assertio Therapeutics Inc is cheap or expensive depends on the assumptions which impact Assertio Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ASRT.

What is Assertio Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, ASRT's PE ratio (Price to Earnings) is -0.33 and Price to Sales (PS) ratio is 0.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ASRT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Assertio Therapeutics Inc's stock?

In the past 10 years, Assertio Therapeutics Inc has provided -0.317 (multiply by 100 for percentage) rate of return.